GlassScriptPhysician profile
Diana M Chen
NPI 1518919091
$16,726.16
in general payments reported to CMS, 2019-2025
64 companies · $3,146 in 2025
The $3,146 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,609 · 2020: $1,427 · 2021: $955 · 2022: $1,506 · 2023: $2,773 · 2024: $3,310 · 2025: $3,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,207 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,207.45 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,849.42 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $2,213.21 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,953.52 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,103.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,055.31 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $698.91 | 2019-2024 | Jardiance, Ofev, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $653.26 | 2023-2025 | |
| Pfizer INC. | $649.83 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $535.83 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $372.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $370.32 | 2023-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $253.43 | 2019-2020 | |
| Exact Sciences Corporation | $243.58 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $233.50 | 2024-2025 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.53 | 2019-2025 | Xifaxan, Trulance |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.